4D Molecular Therapeutics
FDMT
12.59
+0.03
+0.24%
4D Molecular Therapeutics
US · FDMT
#3519 by market cap
Listed 2020
12.59
+0.03
+0.24%
Live - 5344 symbols - heartbeat 215s ago
· 2026-10-08 08:05
Pre-market
12.00
-4.69%
After-hours
12.59
0.00%
- Market cap
- 695.52M
- P/E (TTM)i
- -4.79
- P/Bi
- 1.71
- EPSi
- -2.42
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on FDMT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.07, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +230,194.59% YoY
Margins
- Operating margin
- -187.24%
- Net margin
- -164.43%
Key ratios & quality
- Altman Z-Scorei
- 5.07
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.13M | 6.99M | 13.61M | 18.04M | 3.13M | 20.72M | 37.00K | 85.21M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.17M | 13.90M | 17.24M | 28.01M | 32.91M | 36.49M | 46.58M | 49.06M |
| Research & development | 18.36M | 38.72M | 53.04M | 61.36M | 80.25M | 97.10M | 141.30M | 195.70M |
| Operating profit | -10.40M | -45.63M | -56.66M | -71.33M | -110.03M | -112.87M | -187.84M | -159.55M |
| Pretax profit | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M | -140.11M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M | -140.11M |
| Basic EPS | -1 | -3 | -9 | -3 | -3 | -3 | -3 | -2 |
| Diluted EPS | -0.76 | -3.32 | -8.82 | -2.57 | -3.32 | -2.58 | -2.98 | -2.42 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 14.00K | 15.00K | 90.00K | 85.09M | 3.05M | 3.78M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 12.94M | 11.52M | 11.84M | 12.77M | 11.69M | 12.52M |
| Research & development | 40.70M | 47.95M | 49.44M | 57.61M | 64.98M | 68.28M |
| Operating profit | -53.62M | -59.46M | -61.19M | 14.72M | -73.62M | -77.03M |
| Pretax profit | -47.97M | -54.66M | -56.88M | 19.40M | -68.76M | -72.94M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -47.97M | -54.66M | -56.88M | 19.40M | -68.76M | -72.94M |
| Basic EPS | -1 | -1 | -1 | 0 | -1 | -1 |
| Diluted EPS | -0.86 | -0.98 | -1.01 | 0.43 | -1.01 | -1.04 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 94.07M | 52.51M | 282.66M | 256.28M | 220.51M | 296.59M | 434.93M | 413.13M |
| Cash & ST investments | 91.76M | 49.65M | 276.73M | 247.78M | 213.55M | 288.23M | 424.88M | 402.66M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 96.97M | 58.23M | 288.33M | 353.49M | 261.85M | 339.89M | 560.38M | 566.71M |
| Total current liabilities | 8.05M | 12.96M | 16.74M | 16.34M | 15.73M | 18.95M | 29.15M | 43.99M |
| Short-term debt | -- | -- | -- | 1.23M | 2.66M | 3.15M | 5.64M | 5.59M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 124,556,000.00 | 131,204,000.00 | 31,944,000.00 | 34,380,000.00 | 30,509,000.00 | 32,062,000.00 | 49,778,000.00 | 61,047,000.00 |
| Total equity | -27.59M | -72.97M | 256.39M | 319.11M | 231.34M | 307.83M | 510.61M | 505.66M |
| Retained earnings | -30.03M | -79.03M | -135.68M | -207.00M | -314.49M | -415.33M | -576.20M | -716.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 332.57M | 303.29M | 312.38M | 413.13M | 405.36M | 382.96M |
| Cash & ST investments | 321.44M | 293.23M | 305.06M | 402.66M | 390.89M | 361.33M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 515.73M | 473.64M | 423.98M | 566.71M | 512.91M | 492.62M |
| Total current liabilities | 26.90M | 34.68M | 37.11M | 43.99M | 43.40M | 47.67M |
| Short-term debt | 5.68M | 5.72M | 5.70M | 5.59M | 5.49M | 5.37M |
| Long-term debt | -- | -- | -- | -- | -- | 19.59M |
| Total liabilities | 46,006,000.00 | 52,747,000.00 | 54,999,000.00 | 61,047,000.00 | 61,069,000.00 | 84,956,000.00 |
| Total equity | 469.72M | 420.89M | 368.98M | 505.66M | 451.84M | 407.66M |
| Retained earnings | -624.17M | -678.83M | -735.70M | -716.30M | -785.06M | -858.00M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -16.25M | -36.71M | -50.91M | -69.13M | -86.69M | -75.79M | -134.59M | -109.08M |
| Depreciation & amortization | 697.00K | 1.00M | 1.44M | 3.02M | 3.88M | 5.75M | 6.71M | 7.63M |
| Free cash flow | -16.67M | -39.91M | -51.91M | -78.24M | -98.22M | -78.56M | -138.37M | -109.62M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 105.00K | -2.26M | 205.66M | 114.30M | 0 | 148.34M | 331.41M | 110.72M |
| Ending cash balance | 91.76M | 49.65M | 276.73M | 153.00M | 52.35M | 249.11M | 149.34M | 60.24M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -47.76M | -43.38M | -46.50M | 28.55M | -68.13M | -70.00M |
| Depreciation & amortization | 1.75M | 1.89M | 2.00M | 1.98M | 2.06M | 2.09M |
| Free cash flow | -48.39M | -43.44M | -46.41M | 28.62M | -68.13M | -70.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 110.72M | 9.81M | 21.84M |
| Ending cash balance | 133.53M | 77.16M | 48.56M | 60.24M | 72.49M | 70.37M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -61.82 | -24.78 | -39.06 | -37.40 | -39.31 | -27.57 |
| ROA %i | -15.37 | -63.54 | -32.72 | -22.22 | -34.94 | -33.52 | -35.74 | -24.86 |
| ROIC %i | -- | -- | -61.98 | -23.49 | -37.76 | -39.67 | -43.82 | -30.05 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -40.48 | -33.63 |
| EBIT margin %i | -73.60 | -653.12 | -416.28 | -395.46 | -3,516.52 | -544.65 | -507,678.38 | -187.24 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.68 | 4.05 | 16.88 | 15.69 | 14.02 | 15.65 | 14.92 | 9.39 |
| Quick ratioi | 11.53 | 3.91 | 16.62 | 15.17 | 13.58 | 15.21 | 14.58 | 9.15 |
| Debt / assetsi | -- | -- | 0.00 | 4.65 | 6.16 | 4.32 | 4.39 | 3.78 |
| LT debt / equityi | -- | -- | -- | 4.77 | 5.82 | 3.74 | 3.72 | 3.13 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | 32.97 | 8.48 | -23.49 | 15.04 | -87.29 | 200.86 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -32.97 | -38.87 | -45.38 | -27.57 | -34.92 | -43.25 |
| ROA %i | -30.80 | -35.87 | -40.70 | -24.86 | -31.28 | -37.09 |
| ROIC %i | -36.69 | -42.13 | -47.56 | -30.05 | -37.20 | -44.30 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -884,026.09 | -667,654.55 | -191,982.50 | -187.24 | -203.47 | -214.24 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 12.36 | 8.75 | 8.42 | 9.39 | 9.34 | 8.03 |
| Quick ratioi | 11.95 | 8.46 | 8.22 | 9.15 | 9.01 | 7.68 |
| Debt / assetsi | 4.63 | 4.87 | 5.25 | 3.78 | 4.00 | 7.96 |
| LT debt / equityi | 3.87 | 4.12 | 4.49 | 3.13 | 3.33 | 8.30 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development and commercialization of genetic medicines for specific diseases100.00%
Quote time 2026-10-08 08:05:41 · For reference only, not investment advice and not tailored to your situation.